Evidence map›Paper›PMID 33562869›Full record

ReviewJournal of clinical medicine2021

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome.

Ana Gabaldon-Perez, Victor Marcos-Garces, Jose Gavara, Cesar Rios-Navarro, Gema Miñana, Antoni Bayes-Genis, Oliver Husser, Juan Sanchis, Julio Nunez, Francisco Javier Chorro and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Medical Management of Coronary Artery Disease: An Update.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025
    Review
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Ana Gabaldon-PerezDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.ORCID 0000-0002-2475-0282
Victor Marcos-GarcesDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.ORCID 0000-0001-5565-5547
Jose GavaraINCLIVA Health Research Institute, 46010 Valencia, Spain.
Cesar Rios-NavarroINCLIVA Health Research Institute, 46010 Valencia, Spain.ORCID 0000-0002-6405-6279
Gema MiñanaDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
Antoni Bayes-GenisCentro de Investigación Biomédica en Red-Cardiovascular (CIBER-CV), 28029 Madrid, Spain.
Oliver HusserDepartment of Cardiology, St-Johannes Hospital, 44137 Dortmund, Germany.
Juan SanchisDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.ORCID 0000-0003-0797-8709
Julio NunezDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.ORCID 0000-0003-1672-7119
Francisco Javier ChorroDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
Vicente BodiDepartment of Cardiology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
Universitat de València · ESHospital Clínico Universitario de Valencia · ESINCLIVA Health Research Institute · ESSt.-Johannes-Hospital Dortmund · DEUniversitat Autònoma de Barcelona · ES

Funding

Fondos Europeos de Desarrollo Regional FEDER CIBERCV16/11/00486Fondos Europeos de Desarrollo Regional FEDER CIBER-CV6/11/00420Instituto de Salud Carlos III PI17/01836Instituto de Salud Carlos III PI20/00637
6 · The paper itself

Abstract

Ischemic heart disease (IHD) persists as the leading cause of death in the Western world. In recent decades, great headway has been made in reducing mortality due to IHD, based around secondary prevention. The advent of coronary revascularization techniques, first coronary artery bypass grafting (CABG) surgery in the 1960s and then percutaneous coronary intervention (PCI) in the 1970s, has represented one of the major breakthroughs in medicine during the last century. The benefit provided by these techniques, especially PCI, has been crucial in lowering mortality rates in acute coronary syndrome (ACS). However, in the setting where IHD is most prevalent, namely chronic coronary syndrome (CCS), the increase in life expectancy provided by coronary revascularization is controversial. Over more than 40 years, several clinical trials have been carried out comparing optimal medical treatment (OMT) alone with a strategy of routine coronary revascularization on top of OMT. Beyond a certain degree of symptomatic improvement and lower incidence of minor events, routine invasive management has not demonstrated a convincing effect in terms of reducing mortality in CCS. Based on the accumulated evidence more than half a century after the first revascularization procedures were used, invasive management should be considered in those patients with uncontrolled symptoms despite OMT or high-risk features related to left ventricular function, coronary anatomy, or functional assessment, taking into account the patient expectations and preferences.

Indexed as

chronic coronary syndromecoronary artery diseaseischemiaischemic heart diseasemyocardial revascularizationstress cardiac magnetic resonance

Identifiers

PMID33562869
PMCPMC7914537
OpenAlexW3128328428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.